Company ProfilePremium

Metrics in Balance N.V.

Company Profile Analysis

Ticker: MLMIB.PA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Metrics in Balance N.V. - Company showcase

Year Founded & Workforce

2016

Metrics in Balance N.V. logo

Metrics in Balance N.V. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Metrics in Balance N.V. Overview

FieldDetailSource
Legal nameMetrics in Balance NV (Naamloze Vennootschap; French: SA)NBB FY2024 filing
Former namesNone identifiedNBB filings; KBO extract referenced on IR site
Founding / incorporationDirectors' mandates start 25 Oct 2016. Crossroads Bank for Enterprises (KBO) start date 28 Oct 2016. Some aggregators cite a deed publication of 3 Nov 2016.NBB FY2022/FY2024 filings; Companyweb; Staatsbladmonitor
FoundersGuy De Vreese, Marc Gryspeerdt, Philippe Van AckerTradingView company profile
Incorporation jurisdictionBelgium. Register of Legal Entities (RPR) at the Enterprise Court of Ghent, Ghent division.NBB FY2024 filing
Enterprise / VAT number0665.584.108 / BE0665.584.108NBB FY2024 filing
LEI9676001O8J81JR4HH394IR website
Registered office / HQZuiderlaan 1-3, box 8, 9000 Gent, Belgium. Shared with Remedent NV. Some aggregators list Melle, BE, which conflicts with the filings.NBB FY2024 filing; IR website; TickerSpark
Exchange / marketEuronext Access Paris (MTF, not a regulated market)Euronext listing showcase; IR website
TickerMLMIB (MLMIB.PA)Euronext; IR website
ISINBE0974328602Euronext; IR website
CUSIPNot applicable / not publicly disclosed—
FIGIBBG00KB6ZGH7sustainabilityreports.com
PEA / PEA-PME eligibilityYes / Yes (per French broker data)Easybourse
Listing date15 March 2018 per IR website. The Euronext showcase records the operation date as 20 March 2018.IR website; Euronext
Listing method / priceTechnical admission (private-placement category), 2,050,000 shares at EUR 5.65, valuation EUR 11.6mListing press release, 16 Mar 2018
Listing sponsor (2018)Genesta (Hervé Guyot)Listing press release, 16 Mar 2018
Fiscal year end31 DecemberNBB filings
Shares outstanding4,390,543 registered shares per NBB FY2022/FY2024 filings. The IR website says 4,390,523; Easybourse says 4,390,520.NBB; IR website; Easybourse
Share capitalEUR 12,438,001 (IR site: EUR 12,438,001.27)NBB FY2024 filing; IR website
Employees (parent)0 FTE (FY2024). No staff costs booked in FY2021–FY2024. Historic: c.1.8–2 employees in FY2018–FY2019.Companyweb; NBB filings; FinCheck
Employees (group)——
AuditorNone.NBB FY2022 and FY2024 filings
Market capitalisationc. EUR 144.9k at the last available quote of EUR 0.033/shareSimply Wall St (accessed Oct 2026)
Websitewww.metricsinbalance.comIR website
Principal activity code (Belgium)Rental and leasing of medical and paramedical equipment (Companyweb). Specialised retail of medical and orthopaedic goods (FinCheck).Companyweb; FinCheck

The entity profiled is the one on the identification list. No name change or listing transfer has been identified. The ticker, ISIN, website and Belgian domicile all match.

MetricFY2018FY2019FY2022FY2023FY2024
Employees, parent entity (headcount/FTE)22——0
Staff costs, parent entity (EUR)——000

Sources: FinCheck (FY2018–FY2019); NBB filings (FY2022–FY2024 staff-cost line empty); Companyweb (FY2024 0 FTE).

Metrics in Balance N.V. is a Ghent-based micro-cap holding company. It began as a dental-occlusion diagnostics and custom-splint concept and has since become a small operator of musculoskeletal clinics in the Netherlands. Its founding thesis was that a bad bite can disturb posture and cause pain elsewhere in the body. It combined third-party measurement devices (an intra-oral 3D scanner, a jaw-motion recorder, a 4D spine scanner and a foot-pressure scanner) into a branded diagnostic protocol, followed by custom splint therapy. From 2020 the operating focus moved to chiropractic and physiotherapy clinics under the Dutch "Balans" brand, run through a wholly owned Dutch subsidiary. A DNA-based lifestyle-testing venture ("DNA Talks") followed in 2022. The listed parent has negligible turnover, no employees, a going-concern caveat and a balance sheet dominated by an unimpaired EUR 12.26m subsidiary carrying value. Its market capitalisation is below EUR 0.2m, making it effectively an illiquid shell-like listing over a small private clinic business.


What the company does

MiB describes itself on its corporate website as a holding company with three positions:

  1. Balans healthcare clinics. These are multi-disciplinary chiropractic and physiotherapy clinics in the Netherlands, run through Metrics in Balance Nederland B.V. In mid-2022 the website said the group owned and operated six clinics, in Eindhoven, Malden, Tilburg (two), Venlo and Horst. Venlo and Horst were acquired at the end of June 2022. A greenfield clinic in Rotterdam was planned for September 2022. The stated model was buy-and-build, targeting 20 clinics within 36 months and then other countries.

  2. DNA Talks: lifestyle testing. This is a B2B2C model in which DNA-based lifestyle tests are sold through distributors and independent coaches. Gut-microbiome, blood-analysis and stress tests were described as "coming soon". DNA Talks was incorporated in Belgium in April 2022, and DNA Talks AG followed in Switzerland at the end of June 2022.

  3. Occluso-posture therapy. This is the original MiB concept: measure occlusion and posture, then correct with custom splints. The website describes it as "being tested at the moment".

Source: metricsinbalance.com/company. The page content dates from mid-2022 and has not visibly been updated.

The Company's own description (statutory management report, FY2024)

The board's FY2024 report to the 14 July 2025 AGM gives the following picture (paraphrased from Dutch):

  • During FY2024 the company focused further on the Dutch market. Its emphasis moved towards building out the "Balans" centres, meaning chiropractic and physiotherapy practices.

  • MiB describes itself as a company that performs body measurements starting at the teeth and ending at the feet, which allow a person's posture to be mapped.

  • The commercial focus was the treatment of mechanical back complaints in "Balans rug centra" (back centres), grounded in measurements from the MiB system.

  • Since the balance-sheet date, progress in the Netherlands has continued but has been slower than planned.

  • The company is working on diversification and on tapping an alternative segment.

  • R&D activity was minimal.

Original concept (2018 listing document)

The March 2018 listing press release framed MiB as a measurement-diagnosis-remediation concept for malocclusion. It measures without pain or radiation:

  • the teeth;

  • temporomandibular joint (TMJ) motion and its actual versus ideal position;

  • the spinal column;

  • foot pressure and balance.

The devices named were a Condor intra-oral 3D scanner, a Freecorder, a Diers 4D spine scanner and a pedoscan. The release claimed that roughly 10–20% of posture problems are "ascending" (starting below) and 80–90% "descending" (starting above).

The core monetisable product was custom dental splints: sports splints, protection splints, anti-stress splints and anti-bruxism splints. The stated ambition was to become the world's leading splint company.

MarketScreener and Easybourse summarise the original model as three revenue streams:

  • sale of the medical devices associated with the concept;

  • royalties from practices using the "Metrics in Balance" brand;

  • production and distribution of custom dental splints.

Business and revenue model

Revenue streamMechanismEntityStatus (latest evidence)
Clinic patient fees (chiropractic, physiotherapy)Fee-for-service. Dutch physiotherapy is partly reimbursed through supplementary insurance contracts.Metrics in Balance Nederland B.V. and/or clinic entitiesOperating. "Balans Fysio BV", Boschdijk 391, Eindhoven (balans-rugcentrum.nl email domain), is listed by insurer Zilveren Kruis as contracted for physiotherapy through 2027. Its legal link to MiB is not confirmed in filings.
Ancillary products (insoles, posture wearables, supplements, mattresses)Product resale within clinicsClinic entitiesDescribed in the July 2020 press release; revenue not disclosed
Device sales / brand royaltiesEquipment sale or lease plus royalty from licensed practicesParent (historic)Parent turnover of EUR 300 in FY2022 and FY2023 indicates this stream is dormant
Custom splintsProduct manufacture and saleParent (historic)Concept "being tested" (2022). No disclosed revenue.
DNA lifestyle testsB2B2C via coaches and distributorsDNA Talks BV (BE); DNA Talks AG (CH)25 active coaches in NL and a France distribution contract signed (mid-2022). DNA Talks BV equity was negative at EUR -165,011 at end-FY2024.
Intercompany servicesRecharges to subsidiariesParentReceivables from affiliates of EUR 90,126 (FY2024). Parent FY2024 turnover of EUR 30,100 is consistent with a one-off goods sale (purchases of EUR 30,000 in the same year).

Mix: The product / service / subscription / licensing split is not publicly disclosed at group level. At parent level, revenue is de minimis and irregular.

Value-chain position, customers and end-markets

DimensionCharacterisation
Customer typesPatients with chronic back, neck and posture-related pain (B2C). Historically, dental and allied-health practitioners licensing the concept (B2B). Lifestyle coaches and distributors for DNA tests (B2B2C).
End-marketsDutch chiropractic and physiotherapy; European consumer lifestyle and genetic testing; dental occlusion and TMJ-disorder therapy (dormant)
GeographyOperations in the Netherlands; holding in Belgium; a DNA Talks entity in Switzerland; a DNA Talks distribution agreement with France (2022)

MiB sits at the downstream, patient-facing end of the musculoskeletal-care value chain. It does not manufacture the diagnostic hardware, which comes from third parties (Condor, Diers and others). It integrates these devices into a branded protocol and monetises through clinic services and, in principle, splints and test kits.

Independent characterisation

On the evidence available, MiB is best understood as a listed holding shell over a small, loss-making private clinic subsidiary.

  • The listed parent's statutory accounts show EUR 300 of turnover in each of FY2022 and FY2023, and EUR 30,100 in FY2024.

  • Its EUR 12.26m of assets are almost entirely the carrying value of two 100% subsidiaries. Both report negative equity: Metrics in Balance Nederland B.V. at EUR -316,735 and DNA Talks BV at EUR -165,011, both at 31 Dec 2024.

  • No impairment has been booked.

  • The share has traded at EUR 0.03 with no reported movement over the past year (Simply Wall St).

  • The company's own website has not updated its press-release list since July 2020 or its business description since mid-2022.

The diagnostic concept is intellectually distinctive. However, it relies on contested clinical claims linking dental occlusion to whole-body posture, and it has not demonstrated commercial traction at the listed-entity level.

Strategy

Stated strategy themes

Across its disclosures, MiB has articulated four consistent themes (paraphrased):

  1. Root-cause, measurement-led care. Find the origin of chronic pain through objective scanning rather than treating symptoms (2018 listing release; 2020 release).

  2. From "sick-care" to "prevention-care". A multidisciplinary, patient-centric, holistic model, with the company presenting itself as an early mover (2020 release).

  3. Buy-and-build in Dutch musculoskeletal care. Acquire and open "Balans" clinics; targets have been 30 locations (2020) and then 20 clinics within 36 months, followed by other countries (2022 website).

  4. Diversification. Add revenue streams such as DNA Talks lifestyle testing, and pursue an "alternative segment" (FY2022 and FY2024 board reports).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDetailStatusSource
Refinancing / new capitalThe board states it is working on "important additional financing / refinancing" and that talks on financing and/or capital increases are pendingOngoing as of the 14 Jul 2025 AGM; no completion announcedNBB FY2024 report
Cost containment and internal reorganisationPlanned investments slowed and an internal reorganisation carried out to limit lossesImplementedNBB FY2024 valuation-rules note
Diversification into an "alternative segment"Not specified; market research began around end-May 2023 (FY2022 report)No outcome disclosedNBB FY2022 and FY2024 reports
Continued Balans roll-out in the NetherlandsBack-centre build-out, slower than plannedOngoingNBB FY2024 report

Older initiatives (2020–2022): Balans rebrand and the Tilburg greenfield (2020); Venlo and Horst acquisitions and a planned Rotterdam greenfield (2022); DNA Talks launch (BE April 2022, CH June 2022) with a France distribution contract and a target of one distributor per European country.

ESG commitments, cost programmes and medium-term targets

ESG / sustainability commitments: none disclosed.

Cost programme targets: none quantified.

Medium-term financial guidance: none issued. The only quantified targets have been operational: 4 owned locations by end-2020 and at least 30 overall (2020); 20 clinics within 36 months (2022); 250 NL coaches and 2,000 French coaches for DNA Talks (2022). None has been reported as achieved; the latest disclosed network size is 6 clinics (mid-2022).

Products & Services

Balans healthcare clinics (Netherlands)

OfferingDescriptionTarget customerLaunch / latestPricingSource
Balans Rugcentrum: chiropractic careChiropractic treatment of mechanical back and neck complaints, guided by scan-based diagnosis of the "root cause"Adults with chronic back/neck painEindhoven centre acquired 2020; brand in place since 2020—Press release 2 Jul 2020; website
Physiotherapy (Balans Fysio)Physiotherapy, manual therapy and oedema therapy (Eindhoven). Contracted by Zilveren Kruis through 2027.Insured patientsOngoingInsurer-contracted tariffs (not disclosed)Zilveren Kruis directory
Scan-based diagnosticsAdvanced scanning to "pinpoint" pain origin before treatmentClinic patients2,020—Press release 2 Jul 2020
Aftercare and maintenance programmesExercise plans, dietary supplements, mechanical supports (insoles, posture wearables, mattresses)Discharged patients2,020—Press release 2 Jul 2020
Clinic locationsEindhoven, Malden, Tilburg (2), Venlo, Horst; Rotterdam planned (Sep 2022)—Mid-2022 snapshot—Company website

Throughput claim: The two 2020 locations would serve more than 400 patients per week (press release, July 2020). No later throughput data has been disclosed.

DNA Talks: lifestyle testing

OfferingDescriptionChannelStatusSource
DNA lifestyle testGenetic test for lifestyle guidanceCoaches and distributors (B2B2C)25 active coaches in NL (target 250). France distribution contract signed (target 2,000 coaches). Goal of one distributor in each of 26 European countries.Company website (mid-2022)
Gut microbiome testPlannedSame"Coming soon" (2022). Launch not confirmed.Company website
Blood analysisPlannedSame"Coming soon" (2022). Launch not confirmed.Company website
Stress testPlannedSame"Coming soon" (2022). Launch not confirmed.Company website
Customer software platform and webshopProprietary customer platform; new website/webshopOnlineExpected live mid-July 2022. Current status not disclosed.Company website

Occluso-posture therapy (original MiB concept)

OfferingDescription / specificationsTargetYearPricingSource
MiB measurement protocolRadiation-free, painless measurement of teeth, TMJ motion and position, spine and foot pressureDentists, chiropractors, physiotherapists, osteopaths and their patients2016–2018Device sale plus brand royalty (amounts not disclosed)Listing press release 2018; MarketScreener
Condor intra-oral 3D scanner (third-party)Intra-oral optical scanning of the dentition. Condor Technologies NV is linked to Guy De Vreese, who is its managing director.Practitioners2,018—Listing press release; MarketScreener insider profile
Freecorder (third-party)Jaw-motion / TMJ recordingPractitioners2,018—Listing press release
Diers 4D spine scanner (third-party)Optical back-surface and spine analysisPractitioners2,018—Listing press release
Pedoscan (third-party)Plantar pressure and balancePractitioners2,018—Listing press release
MiB custom splintsIndividually made splints in various compounds, colours and thicknesses. Marketed with a claim of perfect fit and higher compliance.Patients with malocclusion; athletes2,018—Listing press release
Sports splintsPerformance and injury-prevention splintAthletes2,018—Listing press release
Protection splintsDental protectionPatients2,018—Listing press release
Anti-stress splintsStress-related clenchingPatients2,018—Listing press release
Anti-bruxism splintsGrinding preventionPatients2,018—Listing press release
Concept status"Being tested at the moment"—Mid-2022—Company website

Financial Narrative

Basis of preparation. All figures are from the non-consolidated statutory accounts of Metrics in Balance NV (parent only) under Belgian GAAP (full "VOL" schema). They were filed with the NBB and approved by the AGMs of 28 Aug 2023 (FY2022) and 14 Jul 2025 (FY2024). FY2020 values come from aggregators summarising the NBB filing (Staatsbladmonitor) because the FY2020 PDF on the IR site is not machine-readable. FY2025 draft statements are posted but are likewise not machine-readable and are treated as not publicly disclosed.

No cash-flow statement is filed: Belgian GAAP does not require one for this entity. These are not group figures. The loss-making clinic operations are excluded.

Income statement (EUR)

Sources: NBB FY2022 filing (FY2022 and FY2021 columns); NBB FY2024 filing (FY2024 and FY2023 columns). EBITDA and EPS are derived. The Belgian "brutomarge" (turnover plus other operating income minus goods minus services) matches Companyweb's "gross margin" series exactly. Simply Wall St presents FY2024 as revenue 30.1k, cost of revenue 49.8k and gross profit -19.7k, a different cost allocation.

Margins and growth (%)

Derived from NBB filings. Margins on such a small and erratic revenue base carry little economic meaning; they are shown for completeness. The FY2021 and FY2024 positive results depend on non-recurring income: a EUR 64,626 gain on disposal of tangible assets in FY2021 and EUR 38,152 of other non-recurring operating income in FY2024.

Revenue CAGR FY2021–FY2024: approx. -18.2% per year (EUR 55,024 to EUR 30,100), derived. A five-year CAGR cannot be computed because FY2020 turnover is not publicly disclosed in the sources reviewed.

Longer history (EUR)

The two aggregators differ by EUR 1.2k–3.0k per year on net result, possibly reflecting pre- versus post-allocation figures. Both are shown.

Balance sheet (EUR, 31 December)

Sources: NBB FY2022 and FY2024 filings; Staatsbladmonitor (FY2020 equity and debts); FY2020 retained losses derived from the FY2021 filing. Net financial debt is derived as financial debt (long-term, current portion and short-term) minus cash. "Other short-term debts" of EUR 684,299 at end-FY2024 are not itemised. Their nature is not publicly disclosed; they may include shareholder or related-party current accounts or the 2020 crowdlending notes.

Cash flow (EUR)

No cash-flow statement is filed. Capex is taken from the tangible fixed-asset movement schedule: a EUR 30,000 asset under construction was acquired in FY2022 and disposed of in FY2024. Change in cash is derived from balance-sheet cash.

Ratios

All derived from NBB filings. Where both years were available, averages use opening and closing balances; FY2021 averages use the FY2020 equity of 11,798,460 and FY2020 total assets of 12,275,294 (derived as equity plus liabilities). TickerSpark's ROE of -0.45% and ROIC of -0.39% agree with the FY2022 derivations. The cash conversion cycle is not computable because cost of sales is negligible and volatile, so it is not meaningful.

Commentary on trends, inflections and drivers

Revenue. The parent's turnover has never exceeded EUR 56k. In FY2017 and FY2021, revenue of about EUR 55k probably reflected device or equipment sales or recharges. FY2022 and FY2023 revenue of EUR 300 per year is consistent with a dormant holding. The FY2024 rebound to EUR 30,100 coincides with EUR 30,000 of goods purchases, pointing to a single pass-through sale at a small loss. The board itself attributes the near-absence of sales to a "reorganisation phase" and the focus on the Dutch market (FY2024 valuation-rules note, continuity section).

Profitability. Underlying operating costs (services plus goods, excluding pass-throughs) fell from about EUR 92k in FY2021 to about EUR 16k in FY2024. This reflects cost control at holding level. Reported profits in FY2021 and FY2024 depend entirely on non-recurring income. Excluding it, underlying EBITDA has been negative every year: EUR -37k, -40k, -33k and -19k.

Balance sheet quality. Total assets of EUR 12.6m are 97% a single line: participations in subsidiaries at an unchanged historical cost of EUR 12,261,250. That cost originates in the March 2019 contribution in kind. Both subsidiaries report negative equity at end-FY2024 (combined EUR -481,746). No write-down has been booked, and the valuation rules for financial fixed assets mention only cash deposits, not impairment testing. On a look-through basis, the reported equity of EUR 11.7m is not supported by the subsidiaries' net assets. Any value must rest on future earnings of the clinics, for which no disclosure exists. The absence of an auditor heightens this concern.

Liquidity and leverage. Reported financial leverage is negligible relative to book equity, but this is misleading. Measured against liquid assets, the parent is illiquid:

  • cash was zero at end-FY2024;

  • working capital was EUR -447k;

  • current ratio 0.44x;

  • "other short-term debts" have risen steadily to EUR 684k;

  • interest costs have doubled since FY2022 to EUR 15.2k.

The board has flagged pressure on operating cash flow and an ongoing search for "important additional financing / refinancing" in both the FY2022 and FY2024 reports.

Inflections.

FY2019: recapitalisation: equity moved from EUR -0.37m to EUR +11.8m.

FY2022: bank borrowing: c. EUR 194k from credit institutions, coinciding with the Venlo and Horst acquisitions.

FY2024: marginal return to profit, on non-recurring items only.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdiction / IDOwnershipRoleEquity at last report (EUR)Net result at last report (EUR)Source

Metrics in Balance NV

Belgium, 0665.584.108

Listed parent; Remedent NV c.28.47% (Sep 2020)

Holding; historic device/splint concept

11,706,308 (FY2024)

9,069 (FY2024)

NBB FY2024

Metrics in Balance Nederland B.V.

Netherlands, KvK 70461139, Dr Cuyperslaan 74, 5623 BB Eindhoven

100%

Operates the Balans clinics

-316,735 (FY2024)

-183,586 (FY2024)

NBB FY2024 participations note

DNA Talks BV

Belgium, 0694.872.960, Zuiderlaan 1-3/8, Gent

100% (2,000 shares)

DNA lifestyle testing

-165,011 (FY2024)

404 (FY2024)

NBB FY2024 participations note

DNA Talks AG

Switzerland

Not disclosed in parent filing (may be held by DNA Talks BV or third parties)

Distributor and coach recruitment vehicle

——

Company website

Balans Fysio BV (Eindhoven)

Netherlands

Relationship to MiB not confirmed

Physiotherapy practice using the balans-rugcentrum.nl domain

——

Zilveren Kruis provider directory

“—” = not publicly disclosed.

Segment (proxy) — revenue (EUR)

Segment (proxy) — revenue (EUR)FY2022FY2023FY2024

Parent-company statutory turnover (EUR)

30030030,100

Revenue by Segment (EUR)

Subsidiary — net result (EUR)FY2022FY2024

Metrics in Balance Nederland B.V. net result (EUR)

-168,959-183,586

DNA Talks BV net result (EUR)

-70,005404

Subsidiary — equity (EUR)

Subsidiary — equity (EUR)FY2022FY2024

Metrics in Balance Nederland B.V. equity (EUR)

-84,944-316,735

DNA Talks BV equity (EUR)

-105,682-165,011

Income Statement (EUR) and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Turnover (EUR)

—55,02430030030,100

Other operating income (EUR)

—7716,952581,406

Non-recurring operating income (EUR)

—64,6260038,152

Total operating income (EUR)

—119,72717,25235869,658

Goods for resale, net of stock change (EUR)

—33,72167320032,433

Services and other goods (EUR)

—58,30851,57833,08413,390

Staff costs (EUR)

—0000

Depreciation and amortisation (EUR)

—20,0736,6662,150246

Inventory write-downs (EUR)

—04,50004,021

Other operating costs (EUR)

—120122132391

Gross profit: turnover minus goods (EUR)

—21,303-373100-2,333

Gross margin, Belgian "brutomarge" definition (EUR)

—-36,928-34,999-32,926-14,316

Operating result / EBIT (EUR)

—7,505-46,287-35,20819,178

EBITDA: EBIT plus D&A (EUR)

—27,578-39,621-33,05819,424

Underlying EBITDA excluding non-recurring income (EUR)

—-37,048-39,621-33,058-18,728

Financial income (EUR)

—1,0001,60905,467

Financial costs (EUR)

—5,9118,78115,14815,576

of which interest on debt (EUR)

—3,0267,09314,13515,205

Pre-tax result (EUR)

—2,594-53,459-50,3569,069

Income tax (EUR)

—0000

Net result (EUR)

—2,594-53,459-50,3569,069

EPS basic = diluted, on 4390543 shares (EUR)

—0.0006-0.0122-0.01150.0021

Dividend per share (EUR)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024

Operating margin on turnover (%)

13.6-15,429.0-11,736.063.7

EBITDA margin on turnover (%)

50.1-13,207.0-11,019.364.5

Net margin on turnover (%)

4.7-17,819.7-16,785.330.1

Turnover growth YoY (%)

—-99.50.09,933.3

Balance Sheet (EUR)

MetricFY2017FY2018FY2019

Turnover (EUR)

56,1451,34932,727

Net result, Staatsbladmonitor (EUR)

-230,561-297,759-105,016

Net result, FinCheck (EUR)

-231,755-300,667-107,990

Equity (EUR)

-170,255-370,92211,797,589

Total debts (EUR)

248,189453,730429,667

Balance Sheet (EUR) (FY2020–FY2024)

MetricFY2020FY2021FY2022FY2023FY2024

Formation expenses (EUR)

—8,6272,1891660

Tangible fixed assets (EUR)

—43530,20730,0800

Financial fixed assets: subsidiaries (EUR)

—12,261,25012,261,25012,261,25012,261,250

Inventories (EUR)

—18,21514,97414,9748,521

Trade receivables (EUR)

—137,065267,495233,176181,385

Other receivables (EUR)

—5,0736,6863,008165,729

Cash and equivalents (EUR)

—1,825481900

Total current assets (EUR)

—162,179289,636251,248355,635

Total assets (EUR)

—12,432,49012,583,28112,542,74412,616,885

Share capital (EUR)

12,438,00112,438,00112,438,00112,438,00112,438,001

Retained losses (EUR)

-639,541-636,947-690,406-740,763-731,694

Total equity (EUR)

11,798,46011,801,05411,747,59511,697,23911,706,308

Long-term financial debt (EUR)

—0197,190161,18082,682

of which credit institutions (EUR)

—0155,875116,86435,367

of which other loans (EUR)

—041,31544,31547,315

Current portion of long-term debt (EUR)

—037,91540,32541,335

Short-term financial debt (EUR)

—100,000002

Trade payables (EUR)

—121,521127,328134,44277,451

Other short-term debts (EUR)

—372,150449,804486,188684,299

Accruals (EUR)

—37,76523,45023,37024,806

Total liabilities (EUR)

476,834631,436835,686845,505910,577

Total financial debt (EUR)

—100,000235,105201,505124,019

Net financial debt (EUR)

—98,175234,624201,415124,019

Goodwill and intangibles (EUR)

—0000

Working capital: current assets minus short-term debts (EUR)

—-431,492-325,410-409,708-447,453

Receivables from affiliated companies (EUR)

—73,24794,597103,01590,126

Tax losses carried forward, unrecognised (EUR)

——680,000—718,000

Cash Flow (EUR)

MetricFY2021FY2022FY2023FY2024

Capex: acquisitions of tangible assets (EUR)

030,00000

Dividends paid (EUR)

0000

Share buybacks (EUR)

0000

Change in cash (EUR)

—-1,344-391-90

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024

ROE on average equity (%)

0.02-0.45-0.430.08

ROA on average assets (%)

0.02-0.43-0.400.07

ROIC: EBIT over equity plus financial debt (%)

0.06-0.39-0.300.16

Current ratio (x)

0.270.470.380.44

Financial debt to equity (x)

0.0080.0200.0170.011

Total liabilities to equity (x)

0.0540.0710.0720.078

Net debt to EBITDA (x)

3.56-5.92-6.096.39

Interest coverage: EBIT over interest (x)

2.48-6.53-2.491.26

Asset turnover (x)

0.00440.00000.00000.0024

Region — revenue (EUR)

Region — revenue (EUR)FY2022FY2023FY2024

Belgium (parent turnover) (EUR)

30030030,100

Valuation Snapshot

MetricValueSource

Last available price

EUR 0.033

Simply Wall St

Market cap

c. EUR 144.9k

Simply Wall St

1-year change

0%

Simply Wall St

3-year change

-89.0%

Simply Wall St

5-year change

-98.9%

Simply Wall St

Since listing (EUR 5.65)

-99.4%

Simply Wall St

52-week range

Reported as USD 0.03–0.12 by TickerSpark; Simply Wall St shows no range

TickerSpark; Simply Wall St

Beta

0.37–0.42 (aggregators; not meaningful given no trading)

TickerSpark; Simply Wall St

Average volume

0

TickerSpark

Price reference — EUR per share

FY2018

FY2019

Reference trade or quote (EUR)

5.656.99

Valuation Multiples

MultipleMiBComment

P/E

c. 16.0x

Simply Wall St. Based on EUR 9,069 of non-recurring-driven profit; not meaningful.

EV/EBITDA

c. 13.8x

Derived: EV of 144.9k + 124.0k net financial debt = EUR 268.9k, over EBITDA of EUR 19,424. Not meaningful.

EV/Sales

c. 8.9x

Derived (268.9k / 30.1k). Not meaningful.

P/B

c. 0.012x

Derived (144.9k / 11.71m). Reflects market scepticism over the participation's carrying value.

Peer comparison

Simply Wall St peer average P/E 20.2x (European medical equipment); no meaningful listed peers

Simply Wall St

Capital Markets

ItemStatus

Analyst coverage / consensus

None. Simply Wall St reports 0 analysts.

Dividend history and policy

No dividend ever paid; no policy disclosed

Buyback authorisations

None disclosed; no treasury shares (NBB)

Warrants / options

None outstanding (IR website; NBB capital note)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Bonds

None listed. A 2020 crowdlending raise of EUR 300k occurred; its residual balance and location (parent or subsidiary) are not disclosed.

Bucket Details

BucketCredit institutions (EUR)Other loans (EUR)Total (EUR)

Within 1 year (current portion)

41,335041,335

1–5 years

35,367035,367

Over 5 years

047,31547,315

Total

76,70247,315124,017

Analyst Conclusions

Management guidance

No quantitative guidance has been issued. The FY2024 board report (July 2025) says management will continue building the business through diversification and an alternative segment in order to gradually achieve better results. It also states that progress in the Netherlands is slower than planned and that significant financing or refinancing is being pursued.

Consensus

None. There is no analyst coverage.

Bull case

  1. Hidden operating value. The Balans clinic network (six sites in 2022, insurer-contracted physiotherapy through 2027) may carry real operating value that the parent-only accounts do not capture. A market cap of EUR 0.14m against an operating clinic group could re-rate sharply on any credible consolidated disclosure.

  2. Refinancing as a catalyst. A successful capital increase or third-party partner, which the board says is under discussion, could fund the buy-and-build in a fragmented Dutch market and use EUR 718k of tax losses.

  3. DNA Talks optionality. DNA Talks BV reached break-even in FY2024 (EUR +404) after a EUR -70k loss in FY2022. A scalable coach channel with a signed France distributor offers asymmetric upside at negligible valuation.

Bear case

  1. Reported equity overstates value. Equity of EUR 11.7m rests on an unimpaired EUR 12.26m participation in subsidiaries whose combined equity is EUR -0.48m. An impairment would leave the parent with roughly EUR -0.55m of equity (derived: 11,706,308 − 12,261,250).

  2. Liquidity is exhausted. Cash is zero, working capital is EUR -447k and short-term other debts have grown every year. The anchor shareholder (Remedent NV) is itself loss-making, with a FY2025 loss of EUR -386k.

  3. Governance and disclosure are inadequate. There is no auditor, no independent directors, no communication since 2020 and no trading. Minority shareholders have neither information nor an exit.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Final FY2025 accounts (AGM due by mid-2026; NBB filing)Confirms whether refinancing closed, whether the subsidiaries were impaired, and the cash position
Any capital increase or Belgian Gazette publicationA dilutive rescue or change of control would redefine the equity story
Statutory auditor appointment or consolidated accountsA prerequisite for credibility
Clinic network status (count, closures, Rotterdam)The core operating driver
Remedent Inc. / Remedent NV financial healthCapacity of the anchor shareholder to support MiB
Euronext Access trading statusRisk of delisting or suspension for lack of activity or disclosure
Belgian Code of Companies art. 7:228 "alarm bell" procedureTriggered if net assets fall below half of capital after an impairment; requires a shareholder meeting on continuity

Analyst verdict

Metrics in Balance N.V. is, on the public record, a listed holding vehicle in financial distress, whose reported book value cannot be reconciled with its subsidiaries' disclosed results.

The company began in 2016 with an intriguing but scientifically contested premise. It proposed that dental occlusion drives whole-body posture, and that this could be measured with a bundle of third-party scanners and corrected with custom splints. That model never produced material revenue at the listed entity, which earned EUR 300 in each of FY2022 and FY2023. Management then moved to Dutch chiropractic and physiotherapy clinics under the Balans brand and launched a DNA lifestyle-testing side venture. Both sit in subsidiaries that report negative equity: EUR -316,735 for the clinic company and EUR -165,011 for DNA Talks at end-FY2024.

The parent's EUR 11.7m of equity therefore depends on an unimpaired EUR 12.26m carrying value from a 2019 contribution in kind. The market values the whole company at about EUR 0.14m, or about 1% of book, which signals near-total disbelief. The board has warned in successive reports about cash-flow pressure and a need for refinancing. Cash was nil at end-FY2024, and the anchor shareholder is itself shrinking.

Governance compounds the problem. There is no auditor, no independent board member, a dense web of related parties around the chairman's other companies, and no market communication since July 2020.

There is residual optionality. If the Balans clinics are genuinely operating and insurer-contracted, a credible recapitalisation or reverse transaction could reveal value that the parent-only accounts hide, and the tax losses and listing have some shell value. That optionality cannot be assessed without consolidated, audited figures.

Verdict: uninvestable on available information. Treat it as a distressed, illiquid special situation with a high probability of impairment, dilution or delisting. Re-evaluate only on publication of audited consolidated accounts or a disclosed recapitalisation.


Source register

#SourceUsed for
1NBB statutory accounts FY2024 (incl. FY2023 comparatives), Metrics in Balance NV, filed 18 Sep 2025Financials, board, subsidiaries, debt schedule, management report
2NBB statutory accounts FY2022 (incl. FY2021 comparatives), filed 29 Aug 2023Financials, board changes, management report
3metricsinbalance.com: Investor Relations, Company, Press Releases, Contact pages (accessed Oct 2026)Listing data, shareholders, structure, business lines
4Listing press release, 16 Mar 2018Listing terms, original concept, devices, sponsor
5Press release, 2 Jul 2020 (also on EIN Presswire, 6 Jul 2020)Crowdlending, Tilburg, Eindhoven, Balans brand, management bios
6Remedent Inc. press release, 29 Apr 2019 (EIN Presswire)2019 contribution in kind; share price
7Euronext IPO showcase (MLMIB)Listing date and price
8FSMA manager-transaction notifications (2021–2023)Insider dealings
9Simply Wall St; TickerSpark; MarketScreener; TradingView; Easybourse; Financial Modeling PrepMarket data, profiles, insider bios
10Companyweb; FinCheck; Staatsbladmonitor; Trends Top; Pappers.beHistoric financials, registration data, Remedent NV figures
11Zilveren Kruis provider directory; ZorgkaartNederland; companydata.com; CB InsightsClinic evidence, competitors
12Swissinfo; SRF; LebensmittelpraxisLifestyle genetic-testing market context

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundEducationSource

Dirk Verstraete

Managing Director (gedelegeerd bestuurder); CEO and Clinical Director

Mandate start 7 Mar 2018 (FY2024 filing); renewed 17 Oct 2022

Chiropractor with "several decades" of experience; founder of Rug- en Nek Centrum Eindhoven; owner of several businesses

Doctorate, University of California, Los Angeles (per MarketScreener)

NBB filings; press release 2020; MarketScreener

Guy De Vreese

Managing Director; Chairman and lead investor

Since 25 Oct 2016 (founder); renewed 17 Oct 2022

Serial dental entrepreneur. Chairman and CEO of Remedent Inc. (since 2008); CEO of Remedent NV (since 2001); managing director of Condor Technologies NV (since 2010); director of Biotech Dental Benelux NV; president of DMDS Ltd. Formerly CEO of Lident NV and DMD NV and co-CEO of Scan4all SAS.

—

NBB filings; MarketScreener

Cavalli Consulting BV (rep. Marc Gryspeerdt)

Non-executive director

Since 25 Oct 2016 (co-founder); renewed 17 Oct 2022

Co-founder

—

NBB filings; TradingView

Philippe Van Acker

Former director

25 Oct 2016 to 17 Oct 2022

Co-founder; also listed as a director of Remedent NV

—

NBB FY2022; Pappers.be

Brecht Hanssens

Investor Relations & Finance (2020)

Current status unknown

——

Press release 2020

Shane De Vreese

CEO of SmileWise, the incubation partner providing marketing, hiring and fundraising (2020)

———

Press release 2020

“—” = not publicly disclosed.

Governance Overview

AttributeAssessment

Board size

3 directors

Independence

None demonstrably independent. Two are executives (and Remedent-linked, in De Vreese's case). The third is a co-founder through a management company.

Committees

No audit, remuneration or nomination committees disclosed

Chair/CEO separation

Formally yes (De Vreese chair, Verstraete CEO), but both are managing directors

Statutory auditor

None appointed

Governance code

None applicable or adopted on Euronext Access

Related-party concentration

Shared address and executive with Remedent; incubation services from SmileWise (led by Shane De Vreese); Condor scanner (De Vreese-led company) in the protocol. The filings report "nihil" for related-party transactions outside normal market conditions.

Board & Management Changes

DateChangeSource

7 Mar 2018

Dirk Verstraete becomes director / managing director. Gazette publication on 4 Apr 2018.

NBB FY2024; IR website

29 Mar 2019

Director resignation and appointment published alongside the capital increase. The Gazette title references both; names are not specified on the IR page.

IR website

17 Oct 2022

Philippe Van Acker leaves; the other three mandates are renewed

NBB FY2022

Major Shareholders

HolderSharesStakeAs ofSource

Remedent NV (99.99% owned by Remedent Inc., OTC: REMI)

1,250,012

c. 28.47%

30 Sep 2020

IR website

Lausha NV (notified as senior executive / board member)

Net position not disclosed; transactions below

—

2022–2023

FSMA

Free float (freely transferable at listing)

1,533,400

74.8% of the 2.05m shares at the time

Apr 2018

IR website

Institutional holders

None disclosed

———

Governance Detail

Publication dateNotifierTypeQuantityPrice (EUR)Amount (EUR)

16 Dec 2021

Guy De Vreese

Purchase

3,1251.605,032.50

11 Feb 2022

Guy De Vreese

Other (non-cash)

79,3410.000.00

4 Mar 2022

Lausha NV

Purchase

5000.62316.08

4 Mar 2022

Lausha NV

Purchase

6000.80489.18

31 Oct 2022

Lausha NV

Purchase

500.3015.05

21 Jun 2023

Lausha NV

Sale

27,0290.297,795.98

Competitive Landscape

Competitors by Segment

ActivityCompetitorCountryPositioning vs MiBRevenueSource of identification

Chiropractic chains (NL)

B.V. Chiropractie Rugcentra A.B. Van Beest D.C.

NL (Heerlen, Weert)

Established multi-site chiropractic group (10-company group per aggregator)

c. USD 1.23m for the Weert entity (aggregator estimate)

companydata.com

Chiropractic chains (NL)

Chiropractie Centraal B.V.

NL

Direct chiropractic competitor

—

companydata.com

Chiropractic (NL)

Path To Health Gorinchem B.V.

NL

Direct competitor

—

companydata.com

Chiropractic (NL)

Rugcentrum Baarn B.V.

NL

"Back centre" positioning similar to Balans Rugcentrum

—

companydata.com

Chiropractic (NL)

Gormley Chiropractie B.V.; Chiropractie Emmen B.V.; Chiropractie Harderwijk B.V.

NL

Regional chiropractic practices

—

companydata.com

Physiotherapy (Eindhoven)

SGE (Stichting Gezondheidscentra Eindhoven) physiotherapy

NL

Large integrated primary-care network in MiB's home city

—

ZorgkaartNederland

Physiotherapy (Eindhoven)

B-Fysic

NL

Multi-site physiotherapy group

—

ZorgkaartNederland

Physiotherapy (Eindhoven)

Activum Fysiotherapie

NL

Multi-site physiotherapy

—

ZorgkaartNederland

DNA lifestyle testing

Novogenia (Salzburg)

AT

Markets lifestyle DNA tests mainly via nutrition advisers, coaches and physiotherapists, the same B2B2C channel as DNA Talks

—

Lebensmittelpraxis (Oct 2024)

DNA testing

23andMe; iGENEA; ProGenom; Soledor

US / CH

Consumer and lifestyle genetic testing incumbents

—

Swissinfo

Posture tech / wearables

Pao (Eindhoven); Think Healthy (US); Jenx (UK)

NL / US / UK

Named by CB Insights as comparables in posture care

—

CB Insights

“—” = not publicly disclosed.

Peer Comparison FY2024

MetricMiB NV (parent)Van Beest Rugcentra (Weert)

Revenue

EUR 30,100 (FY2024)

c. USD 1.23m (aggregator, year n/d)

Operating margin

n.m. (EBIT EUR 19,178 on non-recurring income)

—

R&D intensity

"Minimal"

—

“—” = not publicly disclosed.

Recent Developments

MiB has issued no press releases since 2 July 2020 (company press-release page).

Not identified in the period: * product launches, contract wins, leadership changes, guidance revisions, litigation, regulatory actions, layoffs or hiring announcements.

Company Snapshot

2016

Founded

Gent, Belgium

Headquarters

SWOT Analysis

Strengths

  • Large book equity. EUR 11.71m of reported equity (FY2024), giving balance-sheet headroom against creditor tests on paper.
  • Low financial debt. Bank debt fell from EUR 193.8k (FY2022) to EUR 76.7k (FY2024), including the current portion.
  • Established Dutch footprint. Six clinics in mid-2022 (website), with Eindhoven and Tilburg still listed on ZorgkaartNederland.
  • Insurer relationship. A Zilveren Kruis physiotherapy contract through 2027 for Balans Fysio BV (affiliation unconfirmed).
  • Experienced, dental-industry-connected leadership. The chairman has led Remedent since 2001/2008 and Condor Technologies since 2010.
  • Low holding-level cost base. Services and goods costs fell to EUR 13,390 in FY2024 from EUR 58,308 in FY2021.

Weaknesses

  • No meaningful listed-entity revenue. EUR 300 in each of FY2022 and FY2023 (NBB).
  • Negative-equity subsidiaries. MiB Nederland at EUR -316,735 and DNA Talks at EUR -165,011, while carried at EUR 12.26m with no impairment (NBB FY2024).
  • Zero cash at end-FY2024 and negative working capital of EUR -447k.
  • Disclosure vacuum. No press release since July 2020, no consolidated accounts, and a stale website.
  • Persistent underlying losses. Underlying EBITDA negative every year FY2021–FY2024 (derived).

Opportunities

  • Fragmented Dutch market. Suitable for roll-up if capital can be secured; 291 physiotherapists in Eindhoven alone (ZorgkaartNederland).
  • Refinancing or capital increase. The board says talks are pending (FY2024 report).
  • DNA Talks B2B2C scaling. A France distribution contract is signed (2022 website); DNA Talks BV broke even in FY2024 (EUR +404).
  • Unused tax losses. EUR 718k of cumulative tax losses could shelter future parent profits (FY2024 note).
  • Reverse-merger or shell value. The listing on Euronext Access plus PEA/PEA-PME eligibility could attract a third party (FY2022 report mentions efforts to attract third parties).
  • Prevention-care trend. This supports the multidisciplinary "Balans" proposition articulated in 2020.

Threats

  • Going-concern risk. The board itself cites operating-cash-flow pressure and a need for financing (FY2022 and FY2024 reports).
  • Impairment risk. A write-down of the EUR 12.26m participation would eliminate most of the reported equity.
  • Anchor shareholder weakness. Remedent NV lost EUR 385,552 in FY2025 and its equity fell 15% to EUR 2.26m (Companyweb).
  • Illiquidity. The share price was flat at EUR 0.033 for a year, down 99.4% from the EUR 5.65 listing price (Simply Wall St). This forecloses equity raises at a meaningful value.
  • Contested clinical claims. These underpin the original occlusion-posture concept and expose it to reputational and regulatory challenge.
  • Regulatory tightening on lifestyle genetic tests. Swiss law changes have restricted online lifestyle tests (SRF coverage).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 Jul 2025AGM approves FY2024 accounts and grants directors discharge NBB FY2024 filingRoutine; confirms the board is still in office
14 Jul 2025FY2024 net profit of EUR 9,069 on turnover of EUR 30,100, the first profit since FY2021 NBB FY2024 filingResult driven by EUR 38,152 of non-recurring income
14 Jul 2025Board reports operating-cash-flow pressure and ongoing work on significant financing / refinancing NBB FY2024 reportGoing-concern risk remains live
14 Jul 2025Board states post-balance-sheet progress in the Netherlands is slower than planned NBB FY2024 reportNegative operational signal
14 Jul 2025Subsidiary disclosure: MiB Nederland B.V. FY2024 loss of EUR -183,586 and equity of EUR -316,735 NBB FY2024 participations noteMaterial deterioration at the operating subsidiary
18–20 Sep 2025FY2024 accounts filed with the NBB NBB filing header; CompanywebFiling occurred after the statutory 30-day window following the AGM
30 Oct 2025Anchor shareholder Remedent NV files FY2025 accounts: loss of EUR -385,552, equity of EUR 2.26m, turnover of EUR 62,168 Companyweb (Remedent NV)Weakening capacity of the anchor shareholder to fund MiB
2026 (date n/d)Draft FY2025 statements for MiB posted on the IR site IR websiteContents unverifiable; signals continued reporting
Oct 2026Share quoted at EUR 0.033; zero price change over 1 month, 3 months and 1 year; market cap c. EUR 144.9k Simply Wall StEffectively no liquidity
OngoingBalans Fysio BV (Eindhoven) contracted with Zilveren Kruis for physiotherapy through 2027Evidence that clinic operations under the Balans name continue (affiliation unconfirmed)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (EUR) (FY2022–FY2024): Parent-company statutory turnover rose from EUR 300 in FY2022 to EUR 30,100 in FY2024.
Metrics in Balance N.V. — Revenue by Segment (EUR) (FY2022–FY2024)
Series (EUR)FY2022FY2023FY2024
Parent-company statutory turnover30030030,100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.